(Q38138343)

29 August 2017

title

Infectious and malignant complications of TNF inhibitor therapy in IBD. (English)

1 reference

29 August 2017

0 references

2

Charles N Bernstein

1 reference

29 August 2017

Laura E Targownik

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

17 September 2013

1 reference

The American Journal of Gastroenterology

29 August 2017

published in

1 reference

29 August 2017

volume

108

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1835-42, quiz 1843

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

A population-based study of health-care resource use among infliximab users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Ulcerative colitis and colorectal cancer. A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Hepatosplenic gamma-delta T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.294

21 January 2018

Identifiers

DOI

10.1038/AJG.2013.294

1 reference

29 August 2017

1 reference